Basal insulin
Insulin glargine
INS_GLARGINE
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.61 (-0.87 to -0.35) | 0.27 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.73 (-1.14 to -0.33) | 0.40 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.79 (-0.98 to -0.59) | 0.40 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.79 (-0.97 to -0.58) | 0.44 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.61 (0.12 to 1.12) | 0.12 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.05 (-1.13 to 1.31) | 0.33 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.68 (-1.08 to -0.14) | 0.23 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.81 (-1.65 to 0.83) | 0.31 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Dulaglutide 0.75 mg subcutaneous once weekly | MD 0.11 (-0.29 to 0.44) | 0.17 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Dulaglutide injection | MD 0.14 (-0.41 to 0.66) | 0.20 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Dulaglutide 0.75 mg subcutaneous once weekly | MD 0.15 (-0.26 to 0.49) | 0.13 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Dulaglutide injection | MD 0.17 (-0.35 to 0.66) | 0.15 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | MD 0.67 (0.10 to 1.19) | 0.21 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin degludec with liraglutide injection | MD 0.68 (0.13 to 1.20) | 0.21 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Semaglutide injection | MD 0.71 (-0.33 to 1.65) | 0.12 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 1.47 (0.60 to 2.34) | 0.01 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 1.07 (-0.24 to 2.33) | 0.01 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 2.45 (-0.02 to 5.60) | 0.09 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 1.03 (-4.78 to 7.92) | 0.32 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.18 (1.46 to 2.88) | 0.15 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.13 (1.25 to 3.02) | 0.22 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 2.37 (-1.45 to 6.52) | 0.07 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 1.49 (-3.62 to 7.11) | 0.14 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | MD 3.23 (0.93 to 5.76) | 0.34 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin degludec with liraglutide injection | MD 3.26 (1.24 to 5.50) | 0.33 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Semaglutide injection | MD 8.26 (2.40 to 12.73) | 0.13 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 3.09 (0.91 to 7.08) | 0.28 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 5.08 (1.50 to 11.62) | 0.34 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Tirzepatide 10 mg subcutaneous once weekly | OR 0.13 (0.06 to 0.33) | 0.00 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 1.94 (0.25 to 7.74) | 0.28 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 3.01 (0.29 to 12.29) | 0.38 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 5.07 (1.60 to 10.64) | 0.59 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 5.85 (2.47 to 11.44) | 0.67 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.33 (0.10 to 0.96) | 0.53 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.24 (0.06 to 0.74) | 0.52 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.48 (1.74 to 7.03) | 0.34 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.83 (2.01 to 7.20) | 0.32 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.63 (1.55 to 4.41) | 0.25 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.43 (1.41 to 4.10) | 0.29 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.37 (1.10 to 4.84) | 0.25 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.32 (0.96 to 5.17) | 0.27 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 0.07 (-1.15 to 1.31) | 0.21 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 0.19 (-1.21 to 1.69) | 0.25 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 5.11 (0.04 to 10.29) | 0.25 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 2.19 (-2.28 to 8.19) | 0.28 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 1.10 (-13.04 to 15.20) | 0.28 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 2.70 (-2.69 to 8.26) | 0.13 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 2.02 (-5.52 to 9.56) | 0.17 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.56 (-1.30 to 2.53) | 0.40 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD -0.49 (-3.34 to 2.60) | 0.26 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.94 (0.81 to 1.09) | 0.52 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.91 (0.77 to 1.07) | 0.57 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.52 (0.34 to 0.76) | 0.82 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.49 (0.30 to 0.74) | 0.82 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.27 (0.21 to 0.35) | 0.92 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.30 (0.22 to 0.40) | 0.83 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.47 (0.34 to 0.64) | 0.87 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.56 (0.38 to 0.81) | 0.79 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.47 (0.38 to 0.59) | 0.91 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.51 (0.41 to 0.64) | 0.88 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.44 (0.28 to 0.66) | 0.84 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.48 (0.32 to 0.70) | 0.77 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.02 (0.00 to 0.19) | 0.97 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.01 (0.00 to 0.15) | 0.96 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 0.80 (0.06 to 10.38) | 0.56 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 1.38 (0.11 to 13.39) | 0.41 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.17 (0.02 to 0.83) | 0.82 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.19 (0.03 to 0.99) | 0.76 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.80 (0.05 to 12.45) | 0.50 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.78 (0.05 to 11.14) | 0.51 |
Trials
- NCT05514535Efficacy and Safety of Once-weekly Semaglutide S.C. 2.0 mg as Add-on to Dose-reduced Insulin Glargine vs Titrated Insulin Glargine in Participants With Type 2 Diabetes and Overweight2022 · 573 randomized · 40 weeks
- S0029842020 · 78 randomized · 24 weeks
- Lixilan-O-APA Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Antidiabetic Drug(s)2019 · 878 randomized · 24 weeks
- NCT04093752A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea2019 · 917 randomized · 40 weeks
- Lixilan-L-CNA Randomized, 30-week, Active-controlled, Open-label, 2 Treatment-arm, Parallel Group, Multicenter Study Comparing Efficacy and Safety of iGlarLixi to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled on Basal Insulin With or Without Oral Antidiabetic Drug(s)2019 · 426 randomized · 30 weeks
- NCT03829891A Randomized, Open-label, Controlled,Parallel-group Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus2018 · 68 randomized · 8 weeks
- SURPASS-4Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)2018 · 2,002 randomized · 104 weeks
- S0030762017 · 35 randomized · 24 weeks
- S0030862017 · 159 randomized · 24 weeks
- DUAL™ VIIIA Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus2016 · 1,012 randomized · 104 weeks
- LIXILAN JP-O2A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine on Top of OADs in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)2016 · 521 randomized · 26 weeks
- LIXILAN JP-LA Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs2016 · 513 randomized · 26 weeks
- DUALTM IXA Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i2016 · 420 randomized · 26 weeks
- NCT02325960A Comparison of Exenatide and Insulin Glargine on Glycemic Variability in T2DM Patients Inadequately Controlled With Metformin Monotherapy2015 · 45 randomized · 16 weeks
- SUSTAIN™ 4Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes2014 · 1,089 randomized · 30 weeks
- LixiLan-LA Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)2014 · 736 randomized · 30 weeks
- LIGHT-ONEfficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease2014 · 75 randomized · 26 weeks
- LixiLan-OA Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)2014 · 1,170 randomized · 30 weeks
- GRADEGlycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study2013 · 5,047 randomized · 365.26 weeks
- S0030062013 · 60 randomized · 24 weeks
- DUAL™ VA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)2013 · 557 randomized · 26 weeks
- AWARD-7A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease2012 · 577 randomized · 52 weeks
- NCT01584232A Phase 3 Study of LY2189265 Compared to Insulin Glargine in Patients With Type 2 Diabetes Mellitus on a Sulfonylurea and/or Biguanide2012 · 361 randomized · 26 weeks
- AWARD-CHN2The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea2012 · 774 randomized · 52 weeks
- NCT01476475A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients2011 · 323 randomized · 24 weeks
- NCT01191268The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)2010 · 884 randomized · 52 weeks
- AWARD-2A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride2010 · 810 randomized · 78 weeks
- NCT00935532Parallel Group Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus Treated With Oral Antidiabetic(s)2009 · 427 randomized · 26 weeks
- NCT00766857The Effect of Exenatide Compared to Insulin Glargine on Cardiac Function and Metabolism in Type 2 Diabetic Patients With Congestive Heart Failure: a Randomized Comparator-controlled Trial2009 · 26 weeks
- NCT00838916A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.2009 · 779 randomized · 156 weeks
- NCT00641056Efficacy of Once-Weekly Exenatide Long-Acting Release and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea2008 · 467 randomized · 84 weeks
- LEAD-5Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine Added to Glimepiride and Metformin Combination Therapy in Subjects With Type 2 Diabetes.A Six-month Randomised, Double-blind, Parallel-group, Multi-centre, Multi-national Trial With an Open-label Treat-to-target Insulin Glargine Control Arm.2006 · 581 randomized · 26 weeks
- NCT00360334An Open Label Study Comparing Exenatide With Basal Insulin in Achieving an HbA1c of ≤ 7.4% With Minimum Weight Gain, in Type 2 Diabetes Patients Who Are Not Achieving Adequate HbA1c Control on Oral Anti Diabetic Therapies Alone2006 · 235 randomized · 26 weeks